
Antengene expands commercial presence in APAC with XPOVIO's approval in Indonesia for cancer treatment
Antengene expands commercial presence in APAC with XPOVIO's approval in Indonesia for cancer treatment March 6, 2025 | Thursday | News XPOVIO is the first and only approved XPO1 inhibitor in Indonesia China's oncology firm Antengene Corporation has …